These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18184439)

  • 21. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
    Huang L; Chen T; Chen C; Chen S; Liu Y; Wu J; Shao Z
    World J Surg Oncol; 2013 Nov; 11():307. PubMed ID: 24289519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
    Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V
    Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.
    Stark A; Kapke A; Schultz D; Brown R; Linden M; Raju U
    Breast Cancer Res Treat; 2008 Feb; 107(3):405-14. PubMed ID: 17431759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables.
    Vasou O; Skagias L; Anastasia M; Paulina A; Patsouris E; Politi E
    Cytojournal; 2015; 12():6. PubMed ID: 25838835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.
    Glynn SA; Prueitt RL; Ridnour LA; Boersma BJ; Dorsey TM; Wink DA; Goodman JE; Yfantis HG; Lee DH; Ambs S
    BMC Cancer; 2010 Nov; 10():626. PubMed ID: 21078168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
    Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
    Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
    J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
    Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
    Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis.
    Emi Y; Kitamura K; Shikada Y; Kakeji Y; Takahashi I; Tsutsui S
    Surgery; 2002 Jan; 131(1 Suppl):S217-21. PubMed ID: 11821814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
    Gheni N; Westenberg D
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on correlation between PKIB and pAkt expression in breast cancer tissues.
    Zhang JB; Song W; Wang YY; Liu MG; Sun MM; Liu H
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1264-1269. PubMed ID: 28387904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
    Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
    J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.